| Editor’s Note: The Top Line is taking a 2-week summer break, and the Fierce Life Sciences team will resume with a new episode during the week of September 4th. |
|
September 14, 2023 | 1:00 PM ET Over 50% of life sciences companies are doing patient finding. Are you? Register now to learn about patient finding best practices, use cases and common pitfalls. AIML is here. Be ready with Trinity Life Sciences. .png)
|
|
Today’s Big NewsAug 23, 2023 |
| By Max Bayer More than six months after Johnson & Johnson merged its infectious disease and vaccine units, the healthcare giant is cutting research and development for the unit altogether, according to sources familiar with the decision. |
|
|
|
| Philadelphia, PA |  |
|
|
By Nick Paul Taylor An “inadvertent disclosure” has given the world a look at Roche’s eagerly anticipated TIGIT data. Having kept its cards close to its chest throughout the phase 3 lung cancer study, the Swiss drugmaker published interim overall survival results Wednesday after they were mistakenly made public. |
By James Waldron The Biomedical Advanced Research and Development Authority (BARDA) has tapped Regeneron for a next-generation COVID-19 antibody therapy, promising up to $326 million in government funds in the hope of getting a candidate into the clinic this year. |
By Annalee Armstrong Going from stealth to a $150 million series B in five months may seem fast, but for Rapport Therapeutics, 10 years of toiling in the labs at Johnson & Johnson beforehand helped the neurological disease biotech accelerate straight from the gate. |
|
Wednesday, August 30, 2023 | 1pm ET/ 10am PT Enzymes have long demonstrated their utility as a green alternative to metal-based catalysts, but the evolution time required can be significant. Join this webinar to learn about an extracellular strategy that reduces the evolution cycle and enables biocatalysis to be used much earlier in development. Register now. 
|
|
By James Waldron Agenus is putting its CTLA-4/PD-1 combo treatment center stage for the time being, while hauling all other unpartnered programs up to the attic for safe keeping. The strategic prioritization will also see 25% of the biotech’s employees headed out to the curb. |
By Nick Paul Taylor Lynk Pharmaceuticals has completed a clean sweep of midphase clinical trials. Having reported primary endpoint hits in two indications earlier this year, the Chinese biotech has maintained its pristine record by linking the JAK1 inhibitor LNK01001 to improvements in adults with active ankylosing spondylitis. |
By Max Bayer After complications with the CRO work behind Pfizer's Lyme disease shot, vaccine R&D chief Annaliesa Anderson, Ph.D., says that much fewer than the planned 18,000 participants will be recruited. |
By Annalee Armstrong PicnicHealth is setting down its lunch basket full of real-world data in the oncology market, and AstraZeneca is bringing dessert. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing. |
By Annalee Armstrong,Gabrielle Masson,Max Bayer We had hoped that our Layoff Tracker would stay retired for a while, but 2023 is starting to look a lot like our old friend 2022 when it comes to layoffs in biotech. |
By Joseph Keenan Global CRO Tigermed has debuted a new international headquarters in Hong Kong in a move to enhance the coordination and management of its worldwide projects. |
By Andrea Park Much like a boy band moving on to its next gig, after more than half a decade leading Zimmer Biomet, Bryan Hanson is taking on the top spot at another medtech giant. |
By Noah Tong In an apparent first case of its kind, two families are suing Florida saying they were illegally kicked off the state's Medicaid rolls. |
|
October 16-17 | Boston, MA Effectively drive collaboration between R&D, clinical and commercial teams to develop an appropriate timeline and practical approach to bringing new products to launch. Book you seat today and save $200! |
|
Whitepaper Learn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
Whitepaper In oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today. Sponsored by: Blue Matter, strategic consultants in the life sciences |
Research Learn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| |
|
